{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:45:44Z","timestamp":1795023944747,"version":"4.10.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009886","name":"Regione Puglia","doi-asserted-by":"crossref","award":["PON \u201cRICERCA E INNOVAZIONE\u201d 2014-2020\u2014Innovazione (D.M. 10 AGOSTO 2021, N. 1062)"],"award-info":[{"award-number":["PON \u201cRICERCA E INNOVAZIONE\u201d 2014-2020\u2014Innovazione (D.M. 10 AGOSTO 2021, N. 1062)"]}],"id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"crossref","award":["CUP H93C22000430007"],"award-info":[{"award-number":["CUP H93C22000430007"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"crossref","award":["CUP H33C22000680006"],"award-info":[{"award-number":["CUP H33C22000680006"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministero dell\u2019Universit\u00e0 e della Ricerca,Italy","award":["CUP H93C22000780006"],"award-info":[{"award-number":["CUP H93C22000780006"]}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"crossref","award":["Id. 23239"],"award-info":[{"award-number":["Id. 23239"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"crossref","award":["2022H9MPZ5"],"award-info":[{"award-number":["2022H9MPZ5"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The Atherogenic Index of Plasma (AIP), calculated by log (Triglycerides\/HDL-C), has been proposed as a marker of atherogenic and cardiovascular risk. Atherosclerosis and Metabolic Dysfunction\u2014Associated Steatotic Liver Disease (MASLD) share some pathogenic features and may be considered clinical manifestations of Metabolic Syndrome. In this study, we aimed to investigate the role of increased AIP as a putative metabolic biomarker for MASLD. 1,496 individuals (49% males and 51% females) underwent clinical examination for Metabolic Syndrome at Internal Medicine Division \u201cC. Frugoni\u201d of University Hospital of Bari, Italy in the period between January 2016 and April 2024. Clinical history was recorded, and physical examination, anthropometric measures, biochemical assessment, and abdomen ultrasound were performed. In the overall population, AIP significantly correlated with fasting glycemia (FPG, r\u2009=\u20090.26, p\u2009&lt;\u20090.0001), HbA1c (r\u2009=\u20090.20, p\u2009&lt;\u20090.0001), LDL (r\u2009=\u20090.11, p\u2009&lt;\u20090.0001) and total cholesterol (r\u2009=\u20090.09; p\u2009&lt;\u20090.0001), and anthropometric measures of obesity BMI (r\u2009=\u20090.37, p\u2009&lt;\u20090.0001) and Waist Circumference (r\u2009=\u20090.44; p\u2009&lt;\u20090.001). We then investigated AIP values in patients with and without dysmetabolic conditions, finding that AIP significantly increased as steatosis worsened (p\u2009&lt;\u20090.001). ROC curves identified an optimal cut-off of 0.31 for accurately diagnosing severe steatosis and AIP values above this cut-off discriminated patients with significantly increased (p\u2009&lt;\u20090.0001) fasting glycemia, LDL, and waist circumference, and were strongly associated (p\u2009&lt;\u20090.0001) with MASLD (LLR 85.3), type 2 diabetes (LLR 85.5), abdominal obesity (LLR 72.9), overweight (LLR 151.8), and systemic obesity (LLR 178.4). The risk for being diagnosed with such conditions was found to be even higher in the subpopulation of patients with severe liver steatosis. To validate our findings, we considered another cohort of patients with and without biopsy-proven liver steatosis (public dataset GSE89632), confirming that a significant increase (p\u2009&lt;\u20090.001) in AIP values could be found in patients with liver steatosis compared to healthy controls. AIP can be considered a specific biomarker of fatty liver disease with high sensitivity for the diagnosis of the severe form of liver steatosis. Considering AIP in the evaluation of patients with liver steatosis may augment the accuracy for diagnosing metabolic impairment and MASLD.<\/jats:p>","DOI":"10.1038\/s41598-025-93141-y","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:04:28Z","timestamp":1742216668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Atherogenic index of plasma identifies subjects with severe liver steatosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Carlo","family":"De Matteis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Novielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Di Buduo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Arconzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella Maria","family":"Gadaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Cariello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Moschetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Crudele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"93141_CR1","doi-asserted-by":"crossref","unstructured":"Dobi\u00e1s\u0306ov\u00e1, M. & Frohlich, J. The plasma parameter log (TG\/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin. Biochem. 34(7), 583\u2013588 (2001).","DOI":"10.1016\/S0009-9120(01)00263-6"},{"issue":"1","key":"93141_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1536\/ihj.23-406","volume":"65","author":"YW Zhi","year":"2024","unstructured":"Zhi, Y. W., Chen, R. G., Zhao, J. W., Zhou, S. X. & He, Z. J. Association between atherogenic index of plasma and risk of incident major adverse cardiovascular events. Int. Heart J. 65(1), 39\u201346 (2024).","journal-title":"Int. Heart J."},{"issue":"1","key":"93141_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3764","volume":"40","author":"D Xiao","year":"2024","unstructured":"Xiao, D. et al. Assessment of six surrogate insulin resistance indexes for predicting cardiometabolic multimorbidity incidence in Chinese middle-aged and older populations: Insights from the China health and retirement longitudinal study. Diabetes Metab. Res. Rev. 40(1), e3764 (2024).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"93141_CR4","doi-asserted-by":"crossref","unstructured":"Xu, F. et al. Higher atherogenic index of plasma is associated with hyperuricemia: A national longitudinal study. Int. J. Endocrinol. 2024, 1\u201312 (2024).","DOI":"10.1155\/2024\/4002839"},{"issue":"1","key":"93141_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12944-018-0828-z","volume":"17","author":"TT Wu","year":"2018","unstructured":"Wu, T. T., Gao, Y., Zheng, Y. Y., Ma, Y. T. & Xie, X. Atherogenic index of plasma (AIP): A novel predictive indicator for the coronary artery disease in postmenopausal women. Lipids Health Dis. 17(1), 197 (2018).","journal-title":"Lipids Health Dis."},{"issue":"7","key":"93141_CR6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1373\/clinchem.2004.031757","volume":"50","author":"MH Tan","year":"2004","unstructured":"Tan, M. H., Johns, D. & Glazer, N. B. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin. Chem. 50(7), 1184\u20131188 (2004).","journal-title":"Clin. Chem."},{"issue":"10","key":"93141_CR7","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1194\/jlr.M040584","volume":"54","author":"M Murgu\u00eda-Romero","year":"2013","unstructured":"Murgu\u00eda-Romero, M. et al. Plasma triglyceride\/HDL-cholesterol ratio, insulin resistance, and cardiometabolic risk in young adults. J. Lipid Res. 54(10), 2795\u20132799 (2013).","journal-title":"J. Lipid Res."},{"issue":"1","key":"93141_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","volume":"31","author":"S Romeo","year":"2020","unstructured":"Romeo, S., Sanyal, A. & Valenti, L. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab. 31(1), 35\u201345 (2020).","journal-title":"Cell Metab."},{"key":"93141_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2024","unstructured":"Stefan, N., Yki-J\u00e4rvinen, H. & Neuschwander-Tetri, B. A. Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 13, 134\u2013148 (2024).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"93141_CR10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/nu13062101","volume":"13","author":"L Crudele","year":"2021","unstructured":"Crudele, L., Piccinin, E. & Moschetta, A. Visceral adiposity and cancer: Role in pathogenesis and prognosis. Nutrients 13(6), 2101 (2021).","journal-title":"Nutrients"},{"issue":"8","key":"93141_CR11","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.3390\/nu15081910","volume":"15","author":"C De Matteis","year":"2023","unstructured":"De Matteis, C. et al. Identification of a novel score for adherence to the mediterranean diet that is inversely associated with visceral adiposity and cardiovascular risk: The Chrono Med Diet Score (CMDS). Nutrients 15(8), 1910 (2023).","journal-title":"Nutrients"},{"key":"93141_CR12","doi-asserted-by":"crossref","unstructured":"Alberti, K. G. M. M., Zimmet, P. & Shaw J. Metabolic syndrome: A new world-wide definition A Consensus Statement from the International Diabetes Federation. Diabet. Med. J. Br. Diabet. Assoc. 23(5), 469\u2013480 (2006).","DOI":"10.1111\/j.1464-5491.2006.01858.x"},{"key":"93141_CR13","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 44(Suppl 1), S15\u2013S33 (2021).","DOI":"10.2337\/dc21-S002"},{"issue":"5","key":"93141_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1381\/096089204323093408","volume":"14","author":"CC Mottin","year":"2004","unstructured":"Mottin, C. C. et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes. Surg. 14(5), 635\u2013637 (2004).","journal-title":"Obes. Surg."},{"key":"93141_CR15","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1966\u20131986 (2023).","journal-title":"J. Hepatol."},{"issue":"5","key":"93141_CR16","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/hep.27695","volume":"61","author":"BM Arendt","year":"2015","unstructured":"Arendt, B. M. et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology 61(5), 1565 (2015).","journal-title":"Hepatology"},{"issue":"7","key":"93141_CR17","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000466","volume":"13","author":"P Pettinelli","year":"2022","unstructured":"Pettinelli, P. et al. Relationship between hepatic gene expression, intestinal microbiota, and inferred functional metagenomic analysis in NAFLD. Clin. Transl. Gastroenterol. 13(7), e00466 (2022).","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"1","key":"93141_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12933-024-02162-w","volume":"23","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. The association between the AIP and undiagnosed diabetes in ACS patients with different body mass indexes and LDL-C levels: Findings from the CCC-ACS project. Cardiovasc. Diabetol. 23(1), 77 (2024).","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"93141_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-023-02108-8","volume":"23","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Evaluation of the role of atherogenic index of plasma in the reversion from Prediabetes to normoglycemia or progression to diabetes: A multi-center retrospective cohort study. Cardiovasc. Diabetol. 23(1), 17 (2024).","journal-title":"Cardiovasc. Diabetol."},{"issue":"Suppl","key":"93141_CR20","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.3350\/cmh.2022.0362","volume":"29","author":"SB Ahn","year":"2023","unstructured":"Ahn, S. B. Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments. Clin. Mol. Hepatol. 29(Suppl), S150\u2013S156 (2023).","journal-title":"Clin. Mol. Hepatol."},{"issue":"3","key":"93141_CR21","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.clnu.2024.02.006","volume":"43","author":"M Kouvari","year":"2024","unstructured":"Kouvari, M. et al. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002\u20132022). Clin. Nutr. 43(3), 900\u2013908 (2024).","journal-title":"Clin. Nutr."},{"issue":"1","key":"93141_CR22","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40001-022-00731-x","volume":"27","author":"S Samimi","year":"2022","unstructured":"Samimi, S. et al. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. Eur. J. Med. Res. 27(1), 112 (2022).","journal-title":"Eur. J. Med. Res."},{"issue":"9","key":"93141_CR23","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/biomedicines10092101","volume":"10","author":"A Ismaiel","year":"2022","unstructured":"Ismaiel, A. et al. Atherogenic index of plasma in non-alcoholic fatty liver disease: Systematic review and meta-analysis. Biomedicines 10(9), 2101 (2022).","journal-title":"Biomedicines"},{"issue":"9","key":"93141_CR24","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3390\/ijms20092358","volume":"20","author":"M Longo","year":"2019","unstructured":"Longo, M. et al. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int. J. Mol. Sci. 20(9), 2358 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"93141_CR25","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","volume":"10","author":"F Zatterale","year":"2019","unstructured":"Zatterale, F. et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front. Physiol. 10, 1607 (2019).","journal-title":"Front. Physiol."},{"issue":"8","key":"93141_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037152","volume":"103","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Association with the plasma atherogenic index with hepatic steatosis and fibrosis in the US population. Medicine (Baltimore) 103(8), e37152 (2024).","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"93141_CR27","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3390\/diagnostics12102426","volume":"12","author":"IC Efrem","year":"2022","unstructured":"Efrem, I. C. et al. A study of biomarkers associated with metabolic dysfunction-associated fatty liver disease in patients with type 2 diabetes. Diagnostics 12(10), 2426 (2022).","journal-title":"Diagnostics"},{"key":"93141_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/jrms.jrms_590_21","volume":"27","author":"A Khosravi","year":"2022","unstructured":"Khosravi, A. et al. Atherogenic index of plasma: A valuable novel index to distinguish patients with unstable atherogenic plaques. J. Res. Med. Sci. 27, 45 (2022).","journal-title":"J. Res. Med. Sci."},{"issue":"3","key":"93141_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.tem.2012.10.004","volume":"24","author":"B Bonamassa","year":"2013","unstructured":"Bonamassa, B. & Moschetta, A. Atherosclerosis: Lessons from LXR and the intestine. Trends Endocrinol. Metab. 24(3), 120\u2013128 (2013).","journal-title":"Trends Endocrinol. Metab."},{"issue":"2","key":"93141_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2010.07.002","volume":"12","author":"G Lo Sasso","year":"2010","unstructured":"Lo Sasso, G. et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 12(2), 187\u2013193 (2010).","journal-title":"Cell Metab."},{"issue":"6","key":"93141_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2021.166116","volume":"1867","author":"M Cariello","year":"2021","unstructured":"Cariello, M. et al. Intracoronary monocyte expression pattern and HDL subfractions after non-ST elevation myocardial infarction. Biochim. Biophys. Acta 1867(6), 166116 (2021).","journal-title":"Biochim. Biophys. Acta"},{"issue":"22","key":"93141_CR32","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1101\/gad.844900","volume":"14","author":"JJ Repa","year":"2000","unstructured":"Repa, J. J. et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14(22), 2819\u20132830 (2000).","journal-title":"Genes Dev."},{"issue":"22","key":"93141_CR33","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1101\/gad.850400","volume":"14","author":"JR Schultz","year":"2000","unstructured":"Schultz, J. R. et al. Role of LXRs in control of lipogenesis. Genes Dev. 14(22), 2831\u20132838 (2000).","journal-title":"Genes Dev."},{"issue":"10","key":"93141_CR34","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1002\/hep4.2053","volume":"6","author":"S Ducheix","year":"2022","unstructured":"Ducheix, S. et al. Reduction in gut-derived MUFAs via intestinal stearoyl-CoA desaturase 1 deletion drives susceptibility to NAFLD and hepatocarcinoma. Hepatol. Commun. 6(10), 2937\u20132949 (2022).","journal-title":"Hepatol. Commun."},{"issue":"5","key":"93141_CR35","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0022-2275(20)42003-6","volume":"37","author":"K Schoonjans","year":"1996","unstructured":"Schoonjans, K., Staels, B. & Auwerx, J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37(5), 907\u2013925 (1996).","journal-title":"J. Lipid Res."},{"issue":"9","key":"93141_CR36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI0215593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109(9), 1125\u20131131 (2002).","journal-title":"J. Clin. Invest."},{"issue":"5","key":"93141_CR37","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1128\/MCB.19.5.3760","volume":"19","author":"M Foretz","year":"1999","unstructured":"Foretz, M. et al. ADD1\/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol. Cell Biol. 19(5), 3760\u20133768 (1999).","journal-title":"Mol. Cell Biol."},{"issue":"24","key":"93141_CR38","doi-asserted-by":"publisher","first-page":"13656","DOI":"10.1073\/pnas.96.24.13656","volume":"96","author":"I Shimomura","year":"1999","unstructured":"Shimomura, I. et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96(24), 13656\u201313661 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"93141_CR39","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/nu5051544","volume":"5","author":"M Gaggini","year":"2013","unstructured":"Gaggini, M. et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 5(5), 1544\u20131560 (2013).","journal-title":"Nutrients"},{"issue":"5","key":"93141_CR40","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/hep.25539","volume":"55","author":"R Lomonaco","year":"2012","unstructured":"Lomonaco, R. et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 55(5), 1389\u20131397 (2012).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93141-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:04:38Z","timestamp":1742216678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93141-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93141"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93141-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethics Committee of the Azienda Ospedaliero-Universitaria Policlinico di Bari (Bari, Italy) in accordance with the requirements of the Declaration of Helsinki. Reference number: n.311, MSC\/PBMC\/2015. Written informed consent for the use of clinical data was obtained from all participants in the study. In accordance with the approved Ethics Committee, only patients who were already 18 years old or more were included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"9136"}}